Aspirin desensitization for patients with aspirin-exacerbated respiratory disease : A randomized double-blind placebo-controlled trial
Copyright © 2015 Elsevier Inc. All rights reserved.
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 160(2015), 2 vom: 15. Okt., Seite 349-57 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2015
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Aspirin-intolerant asthma Desensitization Interferon-gamma Interleukin-10 Quality of life Anti-Inflammatory Agents, Non-Steroidal IL10 protein, human plus... |
| Résumé: | Copyright © 2015 Elsevier Inc. All rights reserved. The effect of aspirin desensitization (AD) on immunologic profile of patients with AERD has been poorly understood. This study is aimed at investigating the effect of AD on clinical and immunological markers of patients with AERD. This randomized double-blind placebo-controlled trial comprised 34 adult patients (67.6% female) with chronic rhinosinusitis, nasal polyps, and aspirin-intolerant asthma. The active group underwent AD over a 2-day period with increasing doses of aspirin (60, 125, 325, and 625 mg), followed by receiving aspirin 625 mg twice daily for 6 months. Symptom scores and medication needs of patients with AERD who have undergone AD were significantly lower compared to the placebo group after 6 months (7.5 ± 3.5 vs. 10.6 ± 3.8 and 9.3 ± 2.0 vs. 11.0 ± 3.1, respectively, all p < 0.05). However, no significant difference was observed in serum concentration of IL-10, IFN-γ, and TGF-β between two groups neither at baseline nor at the end of study |
|---|---|
| Description: | Date Completed 15.12.2015 Date Revised 24.09.2015 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2015.05.012 |